Cargando…

Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways

Glioblastoma (GBM) is the most commonly diagnosed brain tumor that exhibit high mortality rate and chemotherapy resistance is a major clinical problem. Recent studies suggest that estrogen receptor beta (ERβ), may function as a tumor suppressor in GBM. However, the mechanism(s) by which ERβ contribu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Mei, Sareddy, Gangadhara R., Li, Mengxing, Liu, Jinyou, Luo, Yiliao, Venkata, Prabhakar Pitta, Viswanadhapalli, Suryavathi, Tekmal, Rajeshwar R., Brenner, Andrew, Vadlamudi, Ratna K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467924/
https://www.ncbi.nlm.nih.gov/pubmed/30992459
http://dx.doi.org/10.1038/s41598-019-42313-8
_version_ 1783411327501336576
author Zhou, Mei
Sareddy, Gangadhara R.
Li, Mengxing
Liu, Jinyou
Luo, Yiliao
Venkata, Prabhakar Pitta
Viswanadhapalli, Suryavathi
Tekmal, Rajeshwar R.
Brenner, Andrew
Vadlamudi, Ratna K.
author_facet Zhou, Mei
Sareddy, Gangadhara R.
Li, Mengxing
Liu, Jinyou
Luo, Yiliao
Venkata, Prabhakar Pitta
Viswanadhapalli, Suryavathi
Tekmal, Rajeshwar R.
Brenner, Andrew
Vadlamudi, Ratna K.
author_sort Zhou, Mei
collection PubMed
description Glioblastoma (GBM) is the most commonly diagnosed brain tumor that exhibit high mortality rate and chemotherapy resistance is a major clinical problem. Recent studies suggest that estrogen receptor beta (ERβ), may function as a tumor suppressor in GBM. However, the mechanism(s) by which ERβ contributes to GBM suppression and chemotherapy response remains unknown. We examined the role of ERβ in the DNA damage response of GBM cells, and tested whether ERβ sensitizes GBM cells to chemotherapy. Cell viability and survival assays using multiple epitope tagged ERβ expressing established and primary GBM cells demonstrated that ERβ sensitizes GBM cells to DNA damaging agents including temozolomide (TMZ). RNA-seq studies using ERβ overexpression models revealed downregulation of number of genes involved in DNA recombination and repair, ATM signaling and cell cycle check point control. Gene set enrichment analysis (GSEA) suggested that ERβ–modulated genes were correlated negatively with homologous recombination, mismatch repair and G2M checkpoint genes. Further, RT-qPCR analysis revealed that chemotherapy induced activation of cell cycle arrest and apoptosis genes were attenuated in ERβKO cells. Additionally, ERβ overexpressing cells had a higher number of γH2AX foci following TMZ treatment. Mechanistic studies showed that ERβ plays an important role in homologous recombination (HR) mediated repair and ERβ reduced expression and activation of ATM upon DNA damage. More importantly, GBM cells expressing ERβ had increased survival when compared to control GBM cells in orthotopic GBM models. ERβ overexpression further enhanced the survival of mice to TMZ therapy in both TMZ sensitive and TMZ resistant GBM models. Additionally, IHC analysis revealed that ERβ tumors had increased expression of γH2AX and cleaved caspase-3. Using ERβ-overexpression and ERβ-KO GBM model cells, we have provided the evidence that ERβ is required for optimal chemotherapy induced DNA damage response and apoptosis in GBM cells.
format Online
Article
Text
id pubmed-6467924
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-64679242019-04-23 Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways Zhou, Mei Sareddy, Gangadhara R. Li, Mengxing Liu, Jinyou Luo, Yiliao Venkata, Prabhakar Pitta Viswanadhapalli, Suryavathi Tekmal, Rajeshwar R. Brenner, Andrew Vadlamudi, Ratna K. Sci Rep Article Glioblastoma (GBM) is the most commonly diagnosed brain tumor that exhibit high mortality rate and chemotherapy resistance is a major clinical problem. Recent studies suggest that estrogen receptor beta (ERβ), may function as a tumor suppressor in GBM. However, the mechanism(s) by which ERβ contributes to GBM suppression and chemotherapy response remains unknown. We examined the role of ERβ in the DNA damage response of GBM cells, and tested whether ERβ sensitizes GBM cells to chemotherapy. Cell viability and survival assays using multiple epitope tagged ERβ expressing established and primary GBM cells demonstrated that ERβ sensitizes GBM cells to DNA damaging agents including temozolomide (TMZ). RNA-seq studies using ERβ overexpression models revealed downregulation of number of genes involved in DNA recombination and repair, ATM signaling and cell cycle check point control. Gene set enrichment analysis (GSEA) suggested that ERβ–modulated genes were correlated negatively with homologous recombination, mismatch repair and G2M checkpoint genes. Further, RT-qPCR analysis revealed that chemotherapy induced activation of cell cycle arrest and apoptosis genes were attenuated in ERβKO cells. Additionally, ERβ overexpressing cells had a higher number of γH2AX foci following TMZ treatment. Mechanistic studies showed that ERβ plays an important role in homologous recombination (HR) mediated repair and ERβ reduced expression and activation of ATM upon DNA damage. More importantly, GBM cells expressing ERβ had increased survival when compared to control GBM cells in orthotopic GBM models. ERβ overexpression further enhanced the survival of mice to TMZ therapy in both TMZ sensitive and TMZ resistant GBM models. Additionally, IHC analysis revealed that ERβ tumors had increased expression of γH2AX and cleaved caspase-3. Using ERβ-overexpression and ERβ-KO GBM model cells, we have provided the evidence that ERβ is required for optimal chemotherapy induced DNA damage response and apoptosis in GBM cells. Nature Publishing Group UK 2019-04-16 /pmc/articles/PMC6467924/ /pubmed/30992459 http://dx.doi.org/10.1038/s41598-019-42313-8 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhou, Mei
Sareddy, Gangadhara R.
Li, Mengxing
Liu, Jinyou
Luo, Yiliao
Venkata, Prabhakar Pitta
Viswanadhapalli, Suryavathi
Tekmal, Rajeshwar R.
Brenner, Andrew
Vadlamudi, Ratna K.
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title_full Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title_fullStr Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title_full_unstemmed Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title_short Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
title_sort estrogen receptor beta enhances chemotherapy response of gbm cells by down regulating dna damage response pathways
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467924/
https://www.ncbi.nlm.nih.gov/pubmed/30992459
http://dx.doi.org/10.1038/s41598-019-42313-8
work_keys_str_mv AT zhoumei estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT sareddygangadharar estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT limengxing estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT liujinyou estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT luoyiliao estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT venkataprabhakarpitta estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT viswanadhapallisuryavathi estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT tekmalrajeshwarr estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT brennerandrew estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways
AT vadlamudiratnak estrogenreceptorbetaenhanceschemotherapyresponseofgbmcellsbydownregulatingdnadamageresponsepathways